Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC. Mimura N, et al. Among authors: kiziltepe t. Blood. 2012 Jun 14;119(24):5772-81. doi: 10.1182/blood-2011-07-366633. Epub 2012 Apr 26. Blood. 2012. PMID: 22538852 Free PMC article.
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC. Hideshima T, et al. Among authors: kiziltepe t. Br J Haematol. 2007 Sep;138(6):783-91. doi: 10.1111/j.1365-2141.2007.06714.x. Br J Haematol. 2007. PMID: 17760810 Free article.
Fatty acid synthase is a novel therapeutic target in multiple myeloma.
Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC. Okawa Y, et al. Among authors: kiziltepe t. Br J Haematol. 2008 May;141(5):659-71. doi: 10.1111/j.1365-2141.2008.07114.x. Epub 2008 Apr 10. Br J Haematol. 2008. Retraction in: Br J Haematol. 2008 May;141(5):659. PMID: 18410446 Free PMC article. Retracted.
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC. Okawa Y, et al. Among authors: kiziltepe t. Blood. 2009 Jan 22;113(4):846-55. doi: 10.1182/blood-2008-04-151928. Epub 2008 Oct 23. Blood. 2009. PMID: 18948577 Free PMC article.
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC. Ikeda H, et al. Among authors: kiziltepe t. Clin Cancer Res. 2009 Jun 15;15(12):4028-37. doi: 10.1158/1078-0432.CCR-08-2867. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509164
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cristea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC. Ikeda H, et al. Among authors: kiziltepe t. Blood. 2010 Sep 2;116(9):1460-8. doi: 10.1182/blood-2009-06-222943. Epub 2010 May 26. Blood. 2010. PMID: 20505158 Free PMC article.
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC. Catley L, et al. Among authors: kiziltepe t. Blood. 2006 Nov 15;108(10):3441-9. doi: 10.1182/blood-2006-04-016055. Epub 2006 May 25. Blood. 2006. PMID: 16728695 Free PMC article.
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC. Vallet S, et al. Among authors: kiziltepe t. Blood. 2007 Nov 15;110(10):3744-52. doi: 10.1182/blood-2007-05-093294. Epub 2007 Aug 22. Blood. 2007. PMID: 17715391 Free PMC article.
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y, Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR, Anderson KC. Yasui H, et al. Among authors: kiziltepe t. Leukemia. 2007 Mar;21(3):535-40. doi: 10.1038/sj.leu.2404561. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268521
58 results